Efficacy of Biosimilar Adalimumab in the Treatment of Behçet’s Uveitis

ABSTRACT

Purpose

This study aimed to evaluate biosimilar adalimumab’s efficacy and safety in patients with Behçet’s uveitis in Iran.

Methods

We performed a study on patients who mostly (79.2%) had a failure on conventional treatment with the mean follow-up time of 19.24 months (95% confidence interval (CI), 16.52–21.96). All the enrolled patients were anti-tumor necrosis factor (anti-TNF) naiive. The primary endpoint was best-corrected visual acuity (BCVA) improvement, and the secondary endpoints were changes in macular thickness, vitreous haze grade, anterior chamber (AC) cell grade, prednisolone dose, and the incidence of adverse reactions.

Results

Forty-eight patients were enrolled in the study. After adalimumab use, visual acuity improved significantly (p-value˂.001); vitreous haze grade decreased (p-value˂.001), and AC cell grade improved (p-value = .002). Macular thickness decreased, but its change was not statistically significant (p-value = .1). Moreover, adalimumab showed a corticosteroid-sparing effect (p-value = .03).

Conclusion

Biosimilar adalimumab (CinnoRA®) is effective and well-tolerated in Behçet’s uveitis.

KEYWORDS:

• Adalimumab
• Behçet’s disease
• uveitis
• TNF-alpha
• biosimilar
• efficacy
• biADA

Data availability statement

The data that support the findings of this study are available from the corresponding author, M.S., upon reasonable request.

Declaration of interest

N.A. is head of the medical department at Orchid Pharmed company. Other authors have no conflict of interest.